Broad Spectrum Antiviral Activity of Favipiravir (T-705): Protection from Highly Lethal Inhalational Rift Valley Fever

PLoS Neglected Tropical Diseases

Volumn 8, Issue 4, 2014, Pages

  Caroline, Amy L ^a   Powell, Diana S ^a   Bethel, Laura M ^a   Oury, Tim D ^b   Reed, Douglas S ^a,b   Hartman, Amy L ^a,c  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FAVIPIRAVIR; IMMUNOGLOBULIN G;

AEROSOL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; AUTOPSY; BODY TEMPERATURE; BODY WEIGHT; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; IMMUNE RESPONSE; LD 50; LOG RANK TEST; NONHUMAN; RAT; RIFT VALLEY FEVER; VIRUS CULTURE; VIRUS LOAD; VIRUS REPLICATION;

AMIDES; ANIMALS; ANTIVIRAL AGENTS; CHEMOPREVENTION; FEMALE; FEVER; PYRAZINES; RATS; RATS, INBRED WF; RIFT VALLEY FEVER; SURVIVAL ANALYSIS; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 84901258144     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0002790     Document Type: Article

References (62)

1. Samson M, Pizzorno A, Abed Y, Boivin G, (2013) Influenza virus resistance to neuraminidase inhibitors. Antiviral Res 98: 174-185.
2. Burnham AJ, Baranovich T, Govorkova EA, (2013) Neuraminidase inhibitors for influenza B virus infection: Efficacy and resistance. Antiviral Research 100: 520-534.
3. FujiFilm Pharmaceuticals U.S.A Inc. (2011-2013) Pharmacokinetics of Favipiravir in Volunteers With Hepatic Impairment. In: ClinicalTrials.gov, editor. Bethesda, MD: National Library of Medicine.
4. FujiFilm Pharmaceuticals U.S.A Inc. (2010-2012) Dose-Finding Study of Favipiravir in the Treatment of Uncomplicated Influenza. In: ClinicalTrials.gov, editor. US: National Library of Medicine.
5. FujiFilm Pharmaceuticals U.S.A Inc., and Department of Defense. (2012-2013) T-705a Multicenter Study in Adults Subjects With Uncomplicated Influenza (FAVOR). In: ClinicalTrials.gov, editor. US: National Library of Medicine.
6. Kiso M, Takahashi K, Sakai-Tagawa Y, Shinya K, Sakabe S, et al. (2010) T-705 (favipiravir) activity against lethal H5N1 influenza A viruses. Proc Natl Acad Sci U S A 107: 882-887.
7. Furuta Y, Takahashi K, Kuno-Maekawa M, Sangawa H, Uehara S, et al. (2005) Mechanism of action of T-705 against influenza virus. Antimicrob Agents Chemother 49: 981-986.
8. Gowen BB, Smee DF, Wong MH, Hall JO, Jung KH, et al. (2008) Treatment of late stage disease in a model of arenaviral hemorrhagic fever: T-705 efficacy and reduced toxicity suggests an alternative to ribavirin. PLoS One 3: e3725.
9. Gowen BB, Wong MH, Jung KH, Sanders AB, Mendenhall M, et al. (2007) In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections. Antimicrob Agents Chemother 51: 3168-3176.
10. Gowen BB, Wong MH, Jung KH, Smee DF, Morrey JD, et al. (2010) Efficacy of favipiravir (T-705) and T-1106 pyrazine derivatives in phlebovirus disease models. Antiviral Res 86: 121-127.
11. Julander JG, Shafer K, Smee DF, Morrey JD, Furuta Y, (2009) Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106. Antimicrob Agents Chemother 53: 202-209.
12. Julander JG, Smee DF, Morrey JD, Furuta Y, (2009) Effect of T-705 treatment on western equine encephalitis in a mouse model. Antiviral Res 82: 169-171.
13. Morrey JD, Taro BS, Siddharthan V, Wang H, Smee DF, et al. (2008) Efficacy of orally administered T-705 pyrazine analog on lethal West Nile virus infection in rodents. Antiviral Res 80: 377-379.
14. Buys KK, Jung KH, Smee DF, Furuta Y, Gowen BB, (2011) Maporal virus as a surrogate for pathogenic New World hantaviruses and its inhibition by favipiravir. Antivir Chem Chemother 21: 193-200.
15. Furuta Y, Takahashi K, Shiraki K, Sakamoto K, Smee DF, et al. (2009) T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections. Antiviral Res 82: 95-102.
16. Safronetz D, Falzarano D, Scott DP, Furuta Y, Feldmann H, et al. (2013) Antiviral efficacy of favipiravir against two prominent etiological agents of hantavirus pulmonary syndrome. Antimicrob Agents Chemother 57: 4673-4680.
17. Mendenhall M, Russell A, Juelich T, Messina EL, Smee DF, et al. (2011) T-705 (favipiravir) inhibition of arenavirus replication in cell culture. Antimicrob Agents Chemother 55: 782-787.
18. Mendenhall M, Russell A, Smee DF, Hall JO, Skirpstunas R, et al. (2011) Effective oral favipiravir (T-705) therapy initiated after the onset of clinical disease in a model of arenavirus hemorrhagic Fever. PLoS Negl Trop Dis 5: e1342.
19. Al-Afaleq AI, Hussein MF, (2011) The status of Rift Valley fever in animals in Saudi Arabia: a mini review. Vector Borne Zoonotic Dis 11: 1513-1520.
20. Rich KM, Wanyoike F, (2010) An assessment of the regional and national socio-economic impacts of the 2007 Rift Valley fever outbreak in Kenya. Am J Trop Med Hyg 83: 52-57.
21. Konrad SK, Miller SN, (2012) A temperature-limited assessment of the risk of Rift Valley fever transmission and establishment in the continental United States of America. Geospat Health 6: 161-170.
22. Chevalier V, (2013) Relevance of Rift Valley fever to public health in the European Union. Clinical Microbiology and Infection 19: 705-708.
23. Fischer EA, Boender GJ, Nodelijk G, De Koeijer AA, Van Roermund HJ, (2013) The transmission potential of Rift Valley fever virus among livestock in the Netherlands: A modelling study. Vet Res 44: 58.
24. Iranpour M, Turell MJ, Lindsay LR, (2011) Potential for Canadian mosquitoes to transmit rift valley fever virus 1. Journal of the American Mosquito Control Association 27: 363-369.
25. Turell MJ, Britch SC, Aldridge RL, Kline DL, Boohene C, et al. (2013) Potential for mosquitoes (Diptera: Culicidae) from Florida to transmit Rift valley fever virus. Journal of Medical Entomology 50: 1111-1117.
26. Hartley DM, Rinderknecht JL, Nipp TL, Clarke NP, Snowder GD, et al. (2011) Potential Effects of Rift Valley Fever in the United States. Emerg Infect Dis 17: e1.
27. NIAID (2013) NIAID Category A, B, and C Priority Pathogens. Accessed 11/7/2013. Available at: http://www.niaid.nih.gov/topics/biodefenserelated/biodefense/pages/cata.aspx.
28. Department of Health and Human Services (2005) 42 CFR Parts 72, 73 and 42 CFR Part 1003. Posession, Use, and Transfer of Select Agents and Toxins; final rule. Federal Register 70: 13294-13325.
29. U.S. Department of Agriculture (2005) 7 CFR Part 331 and 9 CFR Part 121. Agricultural Bioterrorism Protection Act of 2002; posession, use, and transfer of biological agents and toxins; final rule. Federal Register 70: 13241-13292.
30. Department of Health and Human Services (2009) Biosafety in Microbiological and Biomedical Laboratories. Washington, DC: U.S. Government Printing Office.
31. Bales JM, Powell DS, Bethel LM, Reed DS, Hartman AL, (2012) Choice of inbred rat strain impacts lethality and disease course after respiratory infection with Rift Valley Fever Virus. Front Cell Infect Microbiol 2: 105.
32. Bird BH, Albarino CG, Nichol ST, (2007) Rift Valley fever virus lacking NSm proteins retains high virulence in vivo and may provide a model of human delayed onset neurologic disease. Virology 362: 10-15.
33. Hartman AL, Powell DS, Bethel LM, Caroline AL, Schmid RJ, et al. (2014) Aerosolized Rift Valley Fever virus causes fatal encephalitis in African green monkeys and common marmosets. Journal of Virology 88 (4) (): 2235-2245.
34. Peters CJ, Anderson GW, (1981) Pathogenesis of Rift Valley Fever. Contr Epidem Biostatist 3: 21-41.
35. Peters CJ, Slone TW, (1982) Inbred rat strains mimic the disparate human response to Rift Valley fever virus infection. J Med Virol 10: 45-54.
36. Anderson GW Jr, Slone TW Jr, Peters CJ, (1987) Pathogenesis of Rift Valley fever virus (RVFV) in inbred rats. Microb Pathog 2: 283-293.
37. Anderson GW Jr, Peters CJ, (1988) Viral determinants of virulence for Rift Valley fever (RVF) in rats. Microb Pathog 5: 241-250.
38. Laughlin LW, Meegan JM, Strausbaugh LJ, Morens DM, Watten RH, (1979) Epidemic Rift Valley fever in Egypt: observations of the spectrum of human illness. Trans R Soc Trop Med Hyg 73: 630-633.
39. Meegan JM, (1979) The Rift Valley fever epizootic in Egypt 1977-78. 1. Description of the epizootic and virological studies. Trans R Soc Trop Med Hyg 73: 618-623.
40. Abdel-Wahab KS, El Baz LM, El-Tayeb EM, Omar H, Ossman MA, et al. (1978) Rift Valley Fever virus infections in Egypt: Pathological and virological findings in man. Trans R Soc Trop Med Hyg 72: 392-396.
41. Anderson GW Jr, Lee JO, Anderson AO, Powell N, Mangiafico JA, et al. (1991) Efficacy of a Rift Valley fever virus vaccine against an aerosol infection in rats. Vaccine 9: 710-714.
42. Debing Y, Jochmans D, Neyts J, (2013) Intervention strategies for emerging viruses: use of antivirals. Curr Opin Virol 3: 217-224.
43. Snell NJ, (2001) Ribavirin-current status of a broad spectrum antiviral agent. Expert Opin Pharmacother 2: 1317-1324.
44. Peters CJ, Reynolds JA, Slone TW, Jones DE, Stephen EL, (1986) Prophylaxis of Rift Valley fever with antiviral drugs, immune serum, an interferon inducer, and a macrophage activator. Antiviral Res 6: 285-297.
45. Huggins JW, Robins RK, Canonico PG, (1984) Synergistic antiviral effects of ribavirin and the C-nucleoside analogs tiazofurin and selenazofurin against togaviruses, bunyaviruses, and arenaviruses. Antimicrobial Agents and Chemotherapy 26: 476-480.
46. Kende M, Alving CR, Rill WL, Swartz GM Jr, Canonico PG, (1985) Enhanced efficacy of liposome-encapsulated ribavirin against Rift Valley fever virus infection in mice. Antimicrobial Agents and Chemotherapy 27: 903-907.
47. Kende M, Lupton HW, Rill WL, Levy HB, Canonico PG, (1987) Enhanced therapeutic efficacy of poly(ICLC) and ribavirin combinations against Rift Valley fever virus infection in mice. Antimicrobial Agents and Chemotherapy 31: 986-990.
48. Kirsi JJ, North JA, McKernan PA, Murray BK, Canonico PG, et al. (1983) Broad-spectrum antiviral activity of 2-beta-D-ribofuranosylselenazole-4-carboxamide, a new antiviral agent. Antimicrob Agents Chemother 24: 353-361.
49. Huggins JW, (1989) Prospects for treatment of Viral Hemorrhagic Fevers with Ribavirin, a broad-spectrum antiviral drug. Reviews of Infectious Diseases 11: S750-S761.
50. Borio L, Inglesby T, Peters CJ, Schmaljohn AL, Hughes JM, et al. (2002) Hemorrhagic fever viruses as biological weapons: medical and public health management. JAMA 287: 2391-2405.
51. Smith DR, Steele KE, Shamblin J, Honko A, Johnson J, et al. (2010) The pathogenesis of Rift Valley fever virus in the mouse model. Virology 407: 256-267.
52. Gowen BB, Bailey KW, Scharton D, Vest Z, Westover JB, et al. (2013) Post-exposure vaccination with MP-12 lacking NSs protects mice against lethal Rift Valley fever virus challenge. Antiviral Res 98: 135-143.
53. Reed C, Lin K, Wilhelmsen C, Friedrich B, Nalca A, et al. (2013) Aerosol exposure to Rift Valley fever virus causes earlier and more severe neuropathology in the murine model, which has important implications for therapeutic development. PLoS Negl Trop Dis 7: e2156.
54. Charles PC, Walters E, Margolis F, Johnston RE, (1995) Mechanism of neuroinvasion of Venezuelan equine encephalitis virus in the mouse. Virology 208: 662-671.
55. Monath TP, Cropp CB, Harrison AK, (1983) Mode of entry of a neurotropic arbovirus into the central nervous system. Reinvestigation of an old controversy. Lab Invest 48: 399-410.
56. Martin JW, Christopher GW, Eitzen EM, Jr. (2008) History of Biological Weapons: From Poisoned Darts to Intentional Epidemics. Medical Aspects of Biological Warfare. Washington, DC: Borden Institute.
57. Food and Drug Administration (2002) 21 CFR Parts 314 and 601. Evidence Needed to Demonstrate Effectiveness of New Drugs When Human Efficacy Studies are Not Ethical or Feasible; final rule. Federal Register 67: 37988-37998.
58. National Research Council and the Committee on Animal Models for Assessing Countermeasures to Bioterrorism Agents (2011) Animal Models for Assessing Countermeasures to Bioterrorism Agents: The National Academies Press.
59. Food and Drug Administration (February 5, 2003) FDA approves pyridostigmine bromide as pretreatment against nerve gas. Available at: http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm130342.
60. Food and Drug Administration (December 15, 2006) FDA approves drug to treat cyanide poisoning. Available at: http://www.fda.gov/newsevents/newsroom/pressannouncements/2006/ucm108807.
61. Food and Drug Administration (April 27, 2012) FDA approves new antibacterial treatment for plague. Available at: http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm302220.htm.
62. Layton RC, Mega W, McDonald JD, Brasel TL, Barr EB, et al. (2011) Levofloxacin cures experimental pneumonic plague in African Green monkeys. PLoS Negl Trop Dis 5: e959.